Some tumor characteristics, such as the expression of PD-L1 on cancer cells, a T-cell inflamed profile (T-cell infiltration), and the mutational and/or neoantigen burden are currently known to predict response to ICIs, although the identification of predictive biomarker for ICI-based therapy is still challenging (13, 14). This evidence concerns the gene CD274 and cancer.